Subscribe to RSS Feed

Dr. David Samadi: New Genetic Testing May Prove Better Screening for Prostate Cancer

NEW YORK, May 28, 2015 /PRNewswire/

World renowned robotic prostate cancer surgeon, Dr. David Samadi evaluates the future of how prostate cancer will be diagnosed and treated.

"Due to innovative genetic testing methods, we're getting smarter around not only the diagnosis of prostate cancer but who needs surgery and which patients should watch their cancer. This is a huge shift in this field," said Dr. Samadi, Chairman of Urology and Chief of Robotic Surgery at Lenox Hill Hospital in New York City.

As presented at the 110th Annual Scientific Meeting of the American Urological Association last week, prostate cancer screening needs a more intelligent approach.

Results of the studies revealed how urologists can:

  • Determine frequency of prostate cancer screenings based on PSA levels and risk factors
  • Integrate the Prostate Health Index (PHI) to distinguish aggressive prostate cancer from slow growing forms
  • Apply genetic bio markers for prostate cancer to PSA results to increase accuracy of risk for prostate cancer and avoid unnecessary biopsies
  • Assess genetic profile associated with prostate cancer to better identify high-risk patients and men who may benefit the most from prostate cancer screening

"I see hundreds of men each month and we're already using this approach. The foundation stems from treating each patient individually and now genetic testing can prove even earlier how high a man's risk for prostate cancer is," noted Dr. Samadi.

The game changer here is the role genetic testing plays throughout the entire process, from diagnosis to recurrence. If a man's PSA is elevated, new genetic tests such as the PHI (Prostate Health Index), 4K Score, PcA3, and Prostate Biopsy can further indicate activity around the prostate as well as support whether to get a biopsy or not. If a biopsy returns positive, the next step is directing the right prostate cancer treatment for each patient. Other genetic testing methods such as Prolaris, OncotypeDx, Prostavysion and testing for hereditary PCa and genes like BRCA, will give more information regarding the risk factors, growth rate, aggressiveness and risk of morbidity of the cancer.

"Now that we've moved from Ultrasound to MRI, in combination with these genetic tests, we may actually be to able crack the code and diagnose aggressive prostate cancer earlier. And of course, this leads to the right treatment path for each patient," said Dr. Samadi.

Next is treatment evaluation. If surgery is recommended, the prostate gland can be analyzed to evaluate the likelihood of metastasis and/or biochemical recurrence using the Genome Dx/Decipher test or following the trend of the patient's PSA and how soon after surgery it increases. If the cancer comes back, radiation can be used as a secondary treatment for cases more likely to occur. Being able to identify risk factors earlier is a breakthrough.

"We cannot treat each cancer, such as Gleason scores of 6, 7, or 8+, the same. With prostate cancer, we must individualize the care and now we can with new genetic testing diagnostic tools. We can gather more information about the patient's case at each step of the way," stressed Dr. Samadi.

"Even further, these genetic tests will help us better distinguish candidates for prostate cancer surgery versus watchful waiting and if the disease is more likely to recur."

To take it even further, scientists from the Institute of Cancer Research, UK, analyzed 150 patients with aggressive prostate cancer and found almost 90 percent carried genetic mutations in their tumors. What's more, almost 20 percent carried the BRCA1 and BRCA2 genetic mutations, which have only been associated with their role in breast cancer.

"Perhaps the future of prostate cancer prevention looks more like breast cancer today. In the next 10 years, we may be recommending men to preemptively remove their prostate because their risk for the disease is so high. Being able to smartly distinguish those patients from those with a much lower risk starts with genetic testing," noted Dr. Samadi.

Patients newly diagnosed with prostate cancer can contact world renowned prostate cancer surgeon and urologic oncologist, Dr. David Samadi, for a free consultation. Visit and call 212.365.5000 to set up your free consultation.

Dr. Samadi is a board certified urologic oncologist trained in open and traditional and laparoscopic surgery and is an expert in robotic prostate surgery. He is Chairman of Urology, Chief of Robotic Surgery at Lenox Hill Hospital and Professor of Urology at Hofstra North Shore-LIJ School of Medicine. He is also part of the Fox News Medical A Team as a medical correspondent and the Chief Medical Correspondent for am970 in New York City. He has dedicated his distinguished career to the early detection, diagnosis and treatment of prostate cancer and is considered one of the most prominent surgeons in his field. Learn more at Visit Dr. Samadi's blog at For more comprehensive information about prostate cancer, detecting prostate cancer, how to live with prostate cancer, and how to help support the fight against prostate cancer, please visit

Back to Press Releases

Bookmark Using:
Facebook Twitter LinkedIn Email Yahoo

Share on Facebook

Call to Make an Appointment With Dr. David Samadi:


Click the contact link to learn how Dr. Samadi can help treat your prostate cancer and give you back your quality of life.

* The benefits of robotic surgery cannot be guaranteed as surgery is both patient and procedure specific. Previous surgical results do not guarantee future outcomes.

M. M., New York, USA

"My surgery consisted of arriving at the hospital on Monday morning, surgery shortly after and going home the next day. I could not believe how good I felt".

M.M. Stefanos, Alexandria, Egypt

  "Dear Dr. Samadi, No words could express my gratitude for this successful operation, in which I came out cured, relived without any pain.  This robotic operation was a success because YOU were behind it."

Shlomo P., Israel

הסיפור שלי מתחיל באוגוסט 2010 כאשר תוצאות מבחן ה-PSA שלי הראו תוצאה מדאיגה-6.3 הביופסיה עם אולטרסאונד שנערכה באוקטובר 2010 הראתה תוצאה מדאיגה יותר-גליסון 7 (4+3). וכאן התחיל הסיפור האמיתי שלנו

H. S. MD, Connecticut, USA

It is now more than a week post-op and all is well (including path reports). Once again, I thank Dr. Samadi and all at Mount Sinai for the opportunity to be cared for by the best.?